A Path Forward for Regenerative Medicine-Reference-Cited by-同舟云学术

A Path Forward for Regenerative Medicine

Published:2018-08-03 Issue:4 Volume:123 Page:495-505
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Fanaroff Alexander C.¹²,Morrow Valarie²,Krucoff Mitchell W.¹²,Seltzer Jonathan H.³,Perin Emerson C.⁴,Taylor Doris A.⁴,Miller Leslie W.⁴,Zeiher Andreas M.⁵,Fernández-Avilés Francisco⁶,Losordo Douglas W.⁷⁸,Henry Timothy D.⁹,Povsic Thomas J.¹²

Affiliation:

1. From the Division of Cardiology (A.C.F., M.W.K., T.J.P.)

2. Duke Clinical Research Institute (A.C.F., V.M., M.W.K., T.J.P.)

3. Duke University School of Medicine, Durham, NC; ACI Clinical, Bala Cynwyd, PA (J.H.S.)

4. Stem Cell Center and Regenerative Medicine Research, Texas Heart Institute, Houston (E.C.P., D.A.T., L.W.M.)

5. Department of Cardiology, University of Frankfurt, Germany (A.M.Z.)

6. Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERCV, Madrid, Spain (F.F.-A.)

7. Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL (D.W.L.)

8. Caladrius Biosciences Inc, Basking Ridge, NJ (D.W.L.)

9. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (T.D.H.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference81 articles.

1. Global position paper on cardiovascular regenerative medicine

2. Current State of Stem Cell Therapy for Ischemic Heart Disease

3. U.S. Food and Drug Administration. Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry. 2017. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585414.pdf. Accessed April 20 2018.

4. Balancing Safety and Innovation for Cell-Based Regenerative Medicine

5. Mesoblast Inc. Mesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for Its Cell Therapy in Heart Failure Patients With Left Ventricular Assist Devices. 2017. https://globenewswire.com/news-release/2017/12/21/1268818/0/en/Mesoblast-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-Designation-for-Its-Cell-Therapy-in-Heart-Failure-Patients-With-Left-Ventricular-Assist-Devices.html. Accessed April 20 2018.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MCSand Novel Adjunctive Therapies: An Update;Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease;2023-09-08

2. Mitigation of Fibrosis after Myocardial Infarction in Rats by Using a Porcine Cholecyst Extracellular Matrix;Comparative Medicine;2023-08-27

3. A Minimally Invasive Exosome Spray Repairs Heart after Myocardial Infarction;ACS Nano;2021-06-21

4. Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies;International Journal of Molecular Sciences;2019-03-22

5. Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018;JAMA;2019-03-19